Hwang Ha-na Freed With Fine After Court Clears Drug Charges

Society|
|
By Kim Sung-tae
||
Hwang Ha-na, granddaughter of the founder of Namyang Dairy Products, who was arrested after fleeing overseas while under investigation on drug charges, attends a pre-detention questioning hearing at the Anyang branch of the Suwon District Court in Anyang, Gyeonggi Province, on Dec. 26 last year. Yonhap News - Seoul Economic Daily Society News from South Korea
Hwang Ha-na, granddaughter of the founder of Namyang Dairy Products, who was arrested after fleeing overseas while under investigation on drug charges, attends a pre-detention questioning hearing at the Anyang branch of the Suwon District Court in Anyang, Gyeonggi Province, on Dec. 26 last year. Yonhap News

Hwang Ha-na, 37, the granddaughter of the founder of Namyang Dairy Products, was released after a lower court sentenced her to a fine in a trial over charges of administering methamphetamine to acquaintances.

Judge Park Jun-seop of the Anyang Branch of the Suwon District Court on the 9th sentenced Hwang to a fine of 40 million won on charges including violation of the Act on the Control of Narcotics (psychotropic drugs). Prosecutors had sought a five-year prison term for Hwang.

Hwang was indicted and detained on charges that in July 2023, at an apartment in Seoul's Gangnam district, she encouraged two acquaintances to take methamphetamine and injected them directly with a syringe. When police began a search and seizure targeting one of her two accomplices, she fled to Thailand in December of the same year. She was confirmed to have entered Cambodia illegally and stayed there without returning home, despite knowing that her passport had been invalidated and that she was on a red notice. After she expressed her intention to voluntarily turn herself in late last year, police traveled to Cambodia and arrested her aboard a national carrier at Phnom Penh International Airport.

The court found Hwang not guilty of the drug administration charges. "Based solely on the evidence submitted by the prosecution, it is difficult to conclude that the charges — that the defendant personally administered drugs or had them administered — were proven beyond reasonable doubt," the court said. "The statements of the acquaintances who were present at the scene at the time conflict with one another and are inconsistent with the defendant's statement." The court added that "even the objective results of the drug (test) lack clear evidence to prove the charges."

However, the court found Hwang guilty of some of the flight charges, including departing overseas immediately after coming under investigation.

When Judge Park ordered her release after the sentencing, Hwang covered her face and wiped away tears. Hwang had previously been sentenced in 2019 to one year in prison, suspended for two years, on charges of drug use in 2015. She was then indicted again for taking drugs during the suspended sentence period the following year and was sentenced to one year and eight months in prison by the Supreme Court in 2022.

Original reporting by Kim Sung-tae for Seoul Economic Daily.

AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.

Watch · Seoul Economic Daily

More →
2:30

AI KEY

Preview
Korean Corporate Intelligence HubKOSPI · KOSDAQ · 12 sectors

A live, cap-weighted view of every KOSPI and KOSDAQ sector, with same-day Korean reporting distilled by company — built for foreign investors, correspondents and analysts who need to scan Korea before the next session.

Korea Chaebol Tree

Preview
Families Behind the GroupsKFTC May 2026 · DART filings

An English-first interactive map of Samsung, SK, Hyundai, LG and Lotte — built for foreign investors, correspondents and analysts. Korea translates companies into English. We translate the families behind them.

SIGNAL

Pre-register
English Edition · Capital MarketsM&A · IPO · PE · Fund Flows

Pre-register for SIGNAL English Edition — a premium subscription bringing Korean capital markets coverage (M&A, IPOs, private equity, fund flows) to global institutional investors. First access to the 50% introductory rate.